Welcome to our dedicated page for Mednow news (Ticker: MDNWF), a resource for investors and traders seeking the latest updates and insights on Mednow stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mednow's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mednow's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Mednow Inc. (OTCQX: MDNWF) has introduced new features in its virtual pharmacy applications, including the ability for Ontario pharmacists to assess and prescribe for 13 minor ailments as of January 1, 2023. This initiative, available through Mednow.ca and the Mednow Pharmacy App, allows patients with a valid Ontario health card to receive prescriptions at no cost, funded by the government. Additionally, the platform now offers single sign-on (SSO) capabilities for enterprise clients, enhancing user experience and enabling seamless integration of services. Medication reconciliations are also available through the Mednow platform, which aims to improve patient care and reduce healthcare costs.
Mednow Inc. (TSXV: MNOW, OTCQX: MDNWF) has engaged Gravitas Securities Inc. to assist in offering up to 2,325,581 Units at a Unit Price of $0.43, aiming for gross proceeds of up to $1,000,000. Each Unit includes one Class A common share and one warrant, allowing purchase of a common share at $0.65 for five years. The Company will pay the Agent an 8% cash fee on proceeds and issue Broker Warrants equal to 8% of Units sold. Proceeds will primarily support working capital and corporate purposes, pending TSXV approval. This announcement comes amidst forward-looking statements regarding potential risks related to the Offering, such as regulatory approval delays and market conditions.
Mednow, a leader in virtual pharmacy services, has partnered with Prudent Benefits Administration Services, Inc. (PBAS), a major Canadian third-party administrator, to enhance healthcare access for PBAS clients and members. This partnership will allow over 200,000 Canadians to utilize Mednow's full range of digital healthcare solutions, including online prescriptions and medication delivery services. The initial focus will be on PBAS's student clientele, serving around 30,000 students across Canada, who are identified as ideal users of virtual pharmacy services due to their tech-savviness. The partnership is set to commence in May 2023.
Mednow Inc. (TSXV: MNOW, OTCQX: MDNWF) is set to host its quarterly conference call on March 31, 2023, at 8:30 am EST, discussing its second-quarter 2023 financial results.
Topics will include updates on Mednow's expansion, strategic partnerships, milestones, M&A activities, and financial results. Interested participants can join via the toll-free number 1-800-319-4610 or international toll 1-604-638-5340.
Mednow is recognized for its virtual pharmacy and telemedicine services, aimed at enhancing accessibility and quality in healthcare, including features like free at-home medication delivery and specialized daily dose prescriptions.